• News
  • SAN DIEGO
  • BioTech

AstraZeneca fends off Pfizer with new growth plan

AstraZeneca has outlined plans to grow annual sales to more than $45 billion by 2023 as an independent company, days after the drugmaker rejected a takeover bid by rival Pfizer.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!